Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Research Consultants Inc

Neither a doctor nor a teaching hospital

Research payments

$2,737,371

164 payments

Through program year 2025, Advanced Research Consultants Inc is reported as receiving $2,737,371 in research payments, across 164 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $178,477 11
2024 Research $294,067 21
2023 Research $457,491 52
2022 Research $446,169 36
2021 Research $374,012 25
2020 Research $594,775 16
2019 Research $392,379 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $1,536,634 81 payments
  2. Eli Lilly and Company $737,562 16 payments
  3. Novo Nordisk AS $254,750 52 payments
  4. Biogen, Inc. $92,062 1 payment
  5. Sage Therapeutics, Inc. $76,840 2 payments
  6. ITI, Inc. $36,750 10 payments
  7. Amgen Inc. $1,773 1 payment
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,535,434 80 payments
  2. Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $612,397 4 payments
  3. Nn6535-4725 $254,750 52 payments
  4. Donanemab Follow-On Study: Safety, Tolerability, and Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments $98,235 6 payments
  5. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease $92,062 1 payment
  6. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $76,840 2 payments
  7. A Phase 2, Randomized, Double Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Iti-214 As Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease $29,865 5 payments
  8. Donanemab Follow-On Study: Safety Tolerability and Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments $15,774 2 payments
  9. A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $10,750 2 payments
  10. Iti-214-202 $6,885 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record